Table 5.

Results of analysis^*

Mean (95% UI)	Len-Dex	Bort
Health outcomes
Median time to progression, months	14.08 (13.83–14.32)	6.73 (6.09–7.08)
Mean quality-adjusted life years	3.01 (2.81–3.20)	2.22 (2.02–2.41)
Mean life years	4.14 (4.06–4.21)	3.14 (2.93–3.37)
Economic outcomes
Total therapy cost	€80;77,670 €80;76,509–€80;78,900)	€80;48,928 (€80;48,300–€80;49,556)
Medication	€80;69,450 (€80;68,308–€80;70,550)	€80;40,902 (€80;40,374–€80;41,448)
Monitoring	€80;2943 (€80;2795–€80;3107)	€80;3324 (€80;3141–€80;3518)
Adverse event management	€80;5276 (€80;5082–€80;5485)	€80;4702 (€80;4472–€80;4934)
Cost-effectiveness analysis
Cost per QALY gained	€80;38,268 (€80;27,001–€80;58,065)
Cost per life year gained	€80;29,415 (€80;23,484–€80;37,583)

Note:

^*Discounting outcomes at a 3.5% discount rate.

Abbreviations: QALY, quality-adjusted life years; UI, uncertainty interval.